MELODY
2022
Nirsevimab for Prevention of RSV in Healthy Infants
In 1,490 healthy late-preterm and term infants, a single intramuscular dose of nirsevimab reduced medically attended RSV-associated lower-respiratory-tract infection compared with placebo.
Result
- Absolute difference
- 3.8 points
efficacy74.5
The absolute difference is derived from the event rates.
- Subtopic
- RSV in infants
- Design
- Double-blind RCT
- Relevance
- Supporting: context rather than must-know.
- Source
- Hammitt LL, et al. N Engl J Med. 2022;386(9):837-846.doi 10.1056/NEJMoa2110275
Discussion & critique
Established universal infant RSV monoclonal prophylaxis, now standard in many countries during the RSV season.